November 21, 2019
Whitehead Institute researchers have rewritten the timeline for when and how embryonic cells commit to becoming sex cells, the cells that produce eggs and sperm, and gained insights into the development of testicular cancer.
May 27, 2019
Whitehead Institute and Broad Institute researchers determine that cancer cells commonly change their energy source, creating a weakness that the drug elesclomol exploits to resensitize cancer cells to proteasome inhibitors
April 9, 2019
Researchers have found that certain epigenetic changes in mice that appear to be inherited by offspring can lead to increased cancer rates
July 11, 2018
Whitehead team deploys CRISPR tools to better understand and uncover ways of improving methotrexate, a popular chemotherapy drug.
April 11, 2018
Mouse study links early metastasis to systemic inflammation caused by wound healing
October 20, 2017
Whitehead Member Piyush Gupta has identified a protein stuck in the cell membrane that plays an important role in a cellular pathway crucial for cancer metastasis. The protein is a potential new target for breast cancer therapy that targets the cancer cells' metastatic behavior.
April 3, 2017
Whitehead Institute scientists have identified a gene that could help clinicians discern which patients have aggressive forms of early stage breast cancer, which could prevent hundreds of thousands of women from undergoing unnecessary treatment and save millions of dollars.
February 2, 2017
Investigators at Whitehead Institute and the Broad Institute have succeeded in identifying the set of essential genes—those required for cellular proliferation and survival—in each of 14 human acute myeloid leukemia (AML) cell lines that had previously been characterized by genome sequencing. By combining their “gene essentiality map” with the existing genomic information, their study revealed liabilities in genetically defined subset of cancers that could be exploited for new therapies.
December 26, 2016
The use of proteasome inhibitors to treat cancer has been greatly limited by the ability of cancer cells to develop resistance to these drugs. But Whitehead Institute researchers have found a mechanism underlying this resistance--a mechanism that naturally occurs in many diverse cancer types and that may expose vulnerabilities to drugs that spur the natural cell-death process.
November 10, 2016
Whitehead Institute researchers have determined how the master transcriptional regulator of the heat shock response, known as heat shock factor 1 (HSF1), is controlled in yeast. Understanding how HSF1 works, how it is regulated, and how to fine tune it in a cell-type specific way could lead to therapies for cancer and neurodegenerative diseases.
April 5, 2016
The American Association for Cancer Research (AACR) announced today that Whitehead Institute Founding Member Rudolf Jaenisch is one of 11 newly elected Fellows of the AACR Academy.
March 3, 2016
In a finding with enormous implications for cancer diagnostics and therapeutics, Whitehead Institute scientists have discovered that breaches in looping chromosomal structures known as “insulated neighborhoods” can activate oncogenes capable of fueling aggressive tumor growth.
